| Primary |
| Gestational Diabetes |
33.3% |
| Type 1 Diabetes Mellitus |
18.4% |
| Diabetes Mellitus |
14.0% |
| Drug Use For Unknown Indication |
14.0% |
| Product Used For Unknown Indication |
10.5% |
| Off Label Use |
4.4% |
| Diabetes Mellitus Insulin-dependent |
1.8% |
| Sleep Disorder |
1.8% |
| Type 2 Diabetes Mellitus |
1.8% |
|
| Foetal Exposure During Pregnancy |
12.5% |
| Premature Baby |
12.5% |
| Anaphylactic Shock |
7.5% |
| Head Injury |
7.5% |
| Malaise |
7.5% |
| Cerebrovascular Accident |
5.0% |
| Hyperbilirubinaemia |
5.0% |
| Hyperbilirubinaemia Neonatal |
5.0% |
| Hypoglycaemic Seizure |
5.0% |
| Intentional Overdose |
5.0% |
| Premature Labour |
5.0% |
| Angioedema |
2.5% |
| Blood Glucose Increased |
2.5% |
| Cardiovascular Insufficiency |
2.5% |
| Cellulitis |
2.5% |
| Dizziness |
2.5% |
| Eclampsia |
2.5% |
| Exposure During Pregnancy |
2.5% |
| Foetal Macrosomia |
2.5% |
| Hospitalisation |
2.5% |
|
| Secondary |
| Type 1 Diabetes Mellitus |
25.5% |
| Drug Use For Unknown Indication |
12.7% |
| Gestational Diabetes |
12.7% |
| Foetal Exposure During Pregnancy |
12.1% |
| Type 2 Diabetes Mellitus |
7.6% |
| Insulin-requiring Type 2 Diabetes Mellitus |
7.0% |
| Diabetes Mellitus |
6.4% |
| Systemic Antiviral Treatment |
3.8% |
| Product Used For Unknown Indication |
2.5% |
| Hypertension |
1.9% |
| Analgesic Therapy |
1.3% |
| Off Label Use |
1.3% |
| Psychotic Disorder |
1.3% |
| Schizophrenia, Paranoid Type |
1.3% |
| Antidepressant Therapy |
0.6% |
| Nutritional Supplementation |
0.6% |
| Spinal Disorder |
0.6% |
| Vitamin Supplementation |
0.6% |
|
| Hypoglycaemia |
16.7% |
| Premature Baby |
11.1% |
| Sudden Death |
8.3% |
| Vasculitis |
8.3% |
| Hepatic Steatosis |
5.6% |
| Hyperbilirubinaemia |
5.6% |
| Pregnancy |
5.6% |
| Umbilical Cord Vascular Disorder |
5.6% |
| Angina Pectoris |
2.8% |
| Cardiac Disorder |
2.8% |
| Clonus |
2.8% |
| Diabetes Mellitus Inadequate Control |
2.8% |
| Diabetic Foot |
2.8% |
| Foetal Exposure During Pregnancy |
2.8% |
| Hellp Syndrome |
2.8% |
| Hyperbilirubinaemia Neonatal |
2.8% |
| Intentional Overdose |
2.8% |
| Intra-uterine Death |
2.8% |
| Loss Of Consciousness |
2.8% |
| Malaise |
2.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
29.2% |
| Diabetes Mellitus |
12.7% |
| Hypertension |
10.8% |
| Type 2 Diabetes Mellitus |
10.2% |
| Drug Use For Unknown Indication |
6.8% |
| B-cell Lymphoma |
3.7% |
| Pain |
3.4% |
| Premedication |
3.1% |
| Prophylaxis |
3.0% |
| Gestational Diabetes |
2.2% |
| Type 1 Diabetes Mellitus |
2.1% |
| Idiopathic Thrombocytopenic Purpura |
1.9% |
| Parkinson's Disease |
1.7% |
| Hiv Infection |
1.5% |
| Atrial Fibrillation |
1.4% |
| Coronary Artery Disease |
1.4% |
| Hepatitis C |
1.4% |
| Thrombosis Prophylaxis |
1.4% |
| Rheumatoid Arthritis |
1.3% |
| Cardiac Failure |
1.0% |
|
| Myocardial Infarction |
10.4% |
| Pregnancy |
9.1% |
| Bursitis |
6.5% |
| Tachycardia |
6.5% |
| Pneumonia Primary Atypical |
5.2% |
| Pulmonary Embolism |
5.2% |
| Pyrexia |
5.2% |
| Renal Failure Acute |
5.2% |
| Anaemia |
3.9% |
| Blood Parathyroid Hormone Increased |
3.9% |
| Cerebrovascular Accident |
3.9% |
| Fatigue |
3.9% |
| Gestational Diabetes |
3.9% |
| Myelodysplastic Syndrome |
3.9% |
| Patent Ductus Arteriosus |
3.9% |
| Premature Baby |
3.9% |
| Prostate Cancer |
3.9% |
| Rash |
3.9% |
| Sudden Death |
3.9% |
| Urine Output Decreased |
3.9% |
|
